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Small hepatitis B virus surface protein (S-HBsAg) variant Y100C has been associated with HBsAg-negative phenotype. To
determine whether Y100C substitution yields impaired HBsAg or small amounts of HBsAg that may reduce HBsAg detection
by commercial anti-HBsAg antibodies, two eukaryotic expression plasmids, one containing a wild-type S and the other an S
gene from a Y100C variant, were constructed and their levels of HBsAg compared by ELISA after transfection of HuH7 cells.
Unexpectedly, the extracellular HBsAg levels detected with Y100C plasmid were higher than those observed with the wild-type
plasmid, but without statistical signiﬁcance. We concluded that the Y100C substitution alone did not play a role in reducing
HBsAg amounts or HBsAg aﬃnity by commercial ELISA assay. Further studies on in vitro replication ﬁtness with the complete
genome of HBV isolates displaying or not Y100C substitution may elucidate whether this mutation aﬀects HBV replication and
consequently HBsAg production.
1.Introduction
Hepatitis B virus (HBV) infection still constitutes a major
problemofpublichealth since 360 million peopleworldwide
are chronically infected [1] and exposed to a progressive
disease that may lead to liver cirrhosis and hepatocellular
carcinoma (HCC) [2]. HBV surface antigen (HBsAg) is the
established serological marker for the diagnosis of acute or
chronic HBV infection, and the absence of HBsAg in serum
has been used as a surrogate marker for the absence of DNA
and active viral replication. However, in the last decade,
the development of highly sensitive molecular biology tech-
niques allowed the detection of low levels of HBV DNA in
serumsamplesand/orliverofindividualsnegativeforHBsAg
[3, 4]. This peculiar form of chronic viral infection has been
termed occult HBV infection [5–7].
Diﬀerentmechanisms mayberesponsible fortheabsence
of HBsAg in occult infection, which includes (i) low rate of
HBV replication due to host’s immune response or coinfec-
tion with other infectious agents [8–10], (ii) association of
HBsAg to anti-HBs resulting in the formation of immune
complexes that reduce the circulation of free antigen [5],
or (iii) mutations that inhibit HBsAg expression [11]o r
change HBsAg antigenicity, thus preventing detection by
commercial assays [6, 12–16].
Tyrosine (Y) to cysteine (C) substitution in HBsAg resi-
due 100 (Y100C) has been associated with HBsAg-negative
phenotype in blood donors from Venezuela [17]a n dS p a i n
[18],andisfrequentlyfoundincases ofoccultHBVinfection
in Brazil [12, 19, 20]. Additionally, this substitution has
also been described in one Argentinean patient exhibiting
cocirculation of HBsAg and anti-HBs antibodies [21].
In this study, the role of Y100C substitution in reducing
amountofHBsAgorchangingHBsAgaﬃnitybycommercial
antibodies was investigated by comparison of HBsAg levels
obtainedfromrecombinant plasmidswith orwithoutY100C
substitution.
2.Materialsand Methods
2.1. Construction of HBsAg Expression Plasmids. Two diﬀer-
ent HBV isolates previously characterized in our laboratory
as belonging to HBV subgenotype A1 were used for plasmid2 Hepatitis Research and Treatment
constructions. One isolate had deducedamino acid sequence
for small S gene that was identicalto a consensus sequenceof
wild-type HBV subgenotype A1. Consensus was originated
from an alignment of 100 HBV complete genome sequences
from HBV subgenotype A1 available in GenBank. The
other has a unique Y100C variation in its amino acid
sequence. These two viral strains were used to construct
tworecombinantexpressionplasmidsunderCMVpromoter,
representing a wild-type and a Y100C variant of HBV S gene
(named pcDNA3-SA1 and pcDNA3-Y100C, resp.). Brieﬂy,
HBV DNAs were phenol/chloroform extracted from 250µL
of serum as previously described [22]. The region coding
for S-HBsAg was ampliﬁed by seminested PCR assay. The
ﬁrst round of ampliﬁcation was performed with PS1 and
S2 primers and the second round of ampliﬁcation with S1
and S2 primers, as previously described [12]. S gene PCR
products were cloned into the pCR4 cloning vector (TOPO
TA Cloning Kit for Sequencing, Invitrogen, San Diego,
CA) and subcloned into the EcoRI polylinker region of
the mammalian cell expression vector pcDNA3 (Invitrogen)
as previously described [12]. S-HBsAg expression plasmids
were puriﬁed using S.N.A.P. Midiprep kit (Invitrogen).
HBV nucleotide sequences were determined using BigDye
Terminator kit (Applied Biosystems, CA, USA). Sequenc-
ing reactions were analyzed on an ABI 3730 automated
sequencer (Applied Biosystems). Bioinformatics analysis of
the sequences was performed using MEGA version 3.1
software [23]. Wild-type and Y100C variant sequences
determined have been deposited in the GenBank database,
accession numbers HQ840709 and EF690524, respectively.
2.2. Cell Culture and Transfection Assays. Transient transfec-
tion assays were performed using human hepatoma HuH7
cells maintained in Dulbecco’s modiﬁed Eagle medium
supplemented with 10% fetal bovine serum. Cells were
plated at a density of 5 × 105 cells per well of 6-well
platesandtransfected with 2µgofHBsAgexpressing plasmid
usingFuGENE6(RocheDiagnostics,Mannheim, Germany),
according to the manufacturer’s instructions. Three inde-
pendent transfection assays were performed using three
diﬀerent plasmid preparations of each construct. Culture
supernatants were collected on day 5 after transfection and
clariﬁed by centrifugation at 1,500g for 5min. To evaluate
HBsAg levels inside cells, cell monolayers were washed twice
with phosphate buﬀered saline (PBS), scraped with 1mL of
PBS and centrifuged at 2,500g for 5min. Cell pellets were
frozen/thawedthreetimesandresuspendedin0.4mLofPBS.
Medium and cell extracts were tested for the presence of
HBsAg by a commercial immunoassay (BioELISA HBsAg
colour, Biokit, Barcelona, Spain) after a serial dilution of
10 times in the medium. Mock-transfected HuH7 cells were
used as negative control. HBsAg were quantiﬁed using an
international panel of reference sera containing diﬀerent
concentrations of HBsAg (Boston Biomedica Inc, USA).
HBsAg concentrations of the panel are expressed in ng/mL
and in international units (IU). The detection limit of the
assay is about 0.25ng/mL corresponding to 0.05IU. HBsAg
levels produced by both plasmids were compared using
Mann-Whitney U test with the Statistical Package for Social
Sciences (SPSS, Chicago, IL, USA),version 17.0. Signiﬁcance
was set at a P value of less than .05.
3.Results
Nucleotide sequencing of HBV S gene inserted in recombi-
nantexpressionplasmidspcDNA3-SA1andpcDNA3-Y100C
had conﬁrmedthehighsimilarity betweenbothsequences.A
total of four nucleotide mismatches (T36G, A299G, T432C,
and C666T)betweenpcDNA3-Y100Cand pcDNA3-SA1was
found along the 681-bpfragment ofSgene (notshown). The
A299G is the only nonsynonymous substitution changing
amino acid Y to C in HBsAg residue 100 of small S protein
(Figure 1).
HBsAg levels of medium and cells extracts of pcDNA3-
SA1 and pcDNA3-Y100C constructs, tested in three inde-
pendent transfection assays, were shown in Figure 2.
HBsAg levels detected in medium of transfected cells with
pcDNA3-SA1 ranged from 700 to 800ng/mL (mean and
median values of 740ng/mL (corresponding to 144IU) and
720ng/mL (143IU), resp.), while variation in pcDNA3-
Y100C construct ranged from 790 to 1200ng/mL (mean
and medianvaluesof1.013ng/mL (230IU)and1.050ng/mL
(250IU), resp.). The diﬀerence between the amount of
HBsAg produced by pcDNA3-SA1 and pcDNA3-Y100C
was not signiﬁcant (P = .13). Overall, the mean values
of extracellular HBsAg of pcDNA3-Y100C plasmid were
1.5-fold higher than those observed when the wild-type
plasmid was transfected. Values of HBsAg detected in cell
extracts were much lower than those in medium with both
plasmids (pcDNA3-SA1 and pcDNA3-Y100C), indicating
that S-HBsAg was secreted well in both cases. HBsAg levels
detected in extracellular mediumwere about27-fold and 15-
fold higher than that of cells extracts with pcDNA3-SA1and
pcDNA3-Y100C plasmids, respectively.
4.Discussion
Occult hepatitis B infection has been the subject of several
studies due to diﬀerent clinical contexts associated with it
such as the transmission of HBV in blood transfusion and
organ transplantation, virological and clinical reactivation,
negative inﬂuence on the clinical outcome of other chronic
liver diseases, and development of hepatocellular carcinoma
[6]. The Y100C variation of the small S protein has been
frequently detected in the absence of HBsAg and has
been statistically associated with occult infection in studies
conducted in Venezuela [17] and in Brazil [12, 19, 20].
A variety of explanations for persistence of HBV DNA in
HBsAg-negative individuals have been proposed, including
the occurrence of amino acid substitutions in the HBsAg.
Several HBsAg variants with reduced reactivity against anti-
HBs antibodies have been characterized, most of them with
speciﬁc mutations in the a determinant of HBsAg [24–28].
ViruseswithG145Rreplacementhavebeenalmostinvariably
isolated as a major escape mutant after HBV vaccination
[16, 25, 27, 29]. Besides mutations leading to reducedHepatitis Research and Treatment 3
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Figure 1: Comparison of HBsAg sequences, deduced from recombinant plasmids representing a wild-type (pcDNA3-SA1) and a mutated
(pcDNA3-Y100C) HBV with a consensus sequence of HBV subgenotype A1. Consensus was originated from an alignment of 100 HBV
complete genome sequences from HBV subgenotype A1 available in GenBank.
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Figure 2: Detection of extracellular (upper columns) and intracel-
lular (lower columns) levels of HBsAg by ELISA after transfection
of HuH7 cells. Black columns: SA1; white columns: Y100C variant.
1, 2, 3: HBsAg levels obtained in each transfection assay.
reactivity against anti-HBs antibodies, some mutations may
cause intracellular retention of HBsAg and might play roles
in the several types of situations in which HBV DNA is
detected in the absence of HBsAg [13, 30, 31]. In the
present study, we evaluated if Y100C substitution alone may
inﬂuence the secretion pattern of HBsAg and/or may modify
reactivity against commercial antibodies. Previous studies
have shown that the presence of charged or polar amino
acids in a transmembrane (TM) segment had a crucial role
in endoplasmic reticulum (ER) retention [32, 33]. In the
case of Y100C variant, the replacement by a more polar
amino acid at the end of TM2 segment (position 100) and
the presence of a free sulfhydryl group in the amino acid
C which increases its reactivity allowing the link to other
molecules of C could have altered the conformation of
HBsAg, aﬀecting detection due to impaired recognition of
epitopes and/or secretion due to defective insertion into the
ER membrane and intracellular retention. However, HBsAg
levelsproducedinvitro byY100Cvariant wereslightlyhigher
(about1.5-fold)thanthelevelsproducedbywild-typestrain.
Our ﬁndings indicated that Y100C mutation, which is
potentially capable of altering protein conformation, reduce
neither the production nor secretion of HBsAg.
5.Conclusions
SincepreviousstudieshavedescribedthatY100Cvariationof
the small S protein was frequently detected in the absence of
HBsAg and was statistically associated with occult infection,
the potential inﬂuence of this substitution in the occurrence
of this peculiar type of chronic hepatitis B was investigated
here. Our ﬁndings indicated that Y100C substitution alone
did not negatively aﬀect the detection and/or secretion of
HBsAg. Further studies analyzing the complete genome of
HBV strains with the Y100C substitution may elucidate
whether this mutation aﬀects HBV replication or if there
are mutations in other HBV genomic region that could
explain the association of these variants with occult hepatitis
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